艾迪注射液联合TP方案治疗非小细胞肺癌的临床观察

Clinical Observation of Aidi Injection Combined with TP Regimen in the Treatment of Non-small Cell Lung Cancer

目的:观察艾迪注射液联合TP方案治疗非小细胞肺癌的临床疗效及安全性。方法:将62例非小细胞肺癌患者按随机数字表法分为对照组和观察组,各31例。对照组患者单独采用TP方案治疗,观察组患者在对照组治疗基础上加用艾迪注射液40 ml溶于500 ml 0.9%氯化钠注射液中静脉滴注。两组患者均以21 d为1个周期,共治疗4个周期。比较两组患者治疗前后的炎症因子水平及治疗后的生存质量、近期疗效、满意度和毒副反应发生情况。结果:治疗后,两组患者各炎症因子水平均明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。观察组患者生存质量评分和近期疗效的有效率(分别为80.64%、83.87%)均明显高于对照组(分别为32.25%、64.52%),差异均有统计学意义(P<0.05)。观察组患者的满意度(96.77%)明显高于对照组(77.42%);血小板下降、白细胞下降、肝功能异常的发生率明显低于对照组,差异均有统计学意义(P<0.05)。结论:艾迪注射液联合TP方案对非小细胞肺癌的疗效显著、毒副反应小,且有利于降低炎症因子水平,提高患者的免疫功能及生存质量。

OBJECTIVE：To observe the clinical efficacy and safety of Aidi injection combined with TP regimen in the treatment of non-small cell lung cancer. METHODS：62 patients with non-small cell lung cancer were randomly divided into control group and observation group,31 cases in each group. Control group received TP regimen alone,observation group additionally received 40 ml Aidi injection,dissolved in 500 ml 0.9% Sodium chloride injection by intravenous infusion. 21 d was a treatment course,and it lasted 4 courses. The level of inflammatory cytokines before and after treatment and post-treatment quality of life,short-term efficacy,patients＇ satisfaction and toxicity reactions in 2 groups were compared. RESULTS：After treatment,the level of inflammatory cytokines in 2 groups were significantly lower than before,and observation group was lower than control group,the differences were statistically significant（P〈0.05）. The effective rate of life quality（80.64%） and short-term efficacy（83.87%）in observation group significant were higher than control group（32.25%,64.52%,respectively）,the differences were statistically significant（P〈0.05）. Satisfaction degree（96.77%） in observation group was significantly higher than control group（77.42%）;and the incidences of thrombocytopenia,leukopenia,abnormal liver function were significantly lower than control group,the differences were statistically significant（P〈0.05）. CONCLUSIONS：Aidi injection combined with TP regimen shows good efficacy and little toxicity in the treatment of non-small cell lung cancer,and it helps to reduce the level of inflammatory cytokines in patients,improving immune function and the quality of life of patients.